Why did you develop this detection method for both oncogenic and wart-causing HPV types?
We’re looking a lot at oral fluids. The HPV types present there are not the same as those that have been targeted in other assay systems. Those systems are largely looking at type-specific to the anal-genital region. We picked the two most common types associated with malignancy, 16 and 18; and two most common benign types, 6 and 11; and then we did an E1-based degenerate assay that should pick up any other types of HPV. That will allow us not to miss anything as we’re looking at these different biological specimens. Is this why it is important for your test to be able to distinguish between the more oncogenic types of HPV and the more common types that are not necessarily associated with cervical and other cancers? And also to look between the compartments and understand the differences between the oral and genital compartment. For instance, in our clinical cohort, we saw couples who came in within a year of each other that had the exact same HPV type, which says that this can clearly
